

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 26/08/2022

To
The Manager
Listing Department
BSE Limited
Bombay Stock Exchange,
P. J. Towers, Dalal Street,
Mumbai-400001.

Ref: Scrip code 956084 and ISIN INE988W07019

Subject: Statement of material deviation under Regulation 52(7) Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to Regulation 52(7) Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 please find enclosed herewith the disclosure under the said Regulation for the quarter ended 30th June 2022.

Please take the above information on your records.

Thanking You.

For Genlink Pharma Solutions Pvt Ltd

Anand Shah
Director
DIN: 00597145




GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

DISCLOSURE PURSUANT TO REGULATION 52 (7) OF THE SEBI (LODR), 2015

We hereby state that for the quarter ended 30th June 2022, there is no material deviation in the use of proceeds of Secured Redeemable Non-Convertible Debentures from the objects stated in the offer document.

For Genlink Pharma Solutions Pvt Ltd



Anand Shah
Director
DIN: 00597145



Date: 26/08/2022